Xiaoling Xu
Impact in
- Infectious Diseases top 0.5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 0.5%
- Long-Term Effects of COVID-19
Papers in
-
- Lung Cancer Treatments and Mutations 7
- Lung Cancer Diagnosis and Treatment 6
- Co-authors
- Haiming Wei (4 shared papers)Xiaohu Zheng (3 shared papers)Binqing Fu (3 shared papers)Yonggang Zhou (3 shared papers)Dongsheng Wang (3 shared papers)Tiantian Li (2 shared papers)Aijun Pan (1 shared paper)Wei Sun (1 shared paper)
- Journals
- Frontiers in Oncology (5 papers)OncoTargets and Therapy (4 papers)Translational Lung Cancer Research (3 papers)PLoS ONE (2 papers)LWT (2 papers)
- Partner nations
- ChinaUnited StatesMacao
In The Last Decade
Xiaoling Xu
76 papers receiving 4.2k citations
Xiaoling Xu's Hit Papers
Peers
Comparison fields: 5 of 145
- Infectious Diseases 2.0k
- Neurology 1.1k
- Obstetrics and Gynecology 136
- Cancer Research 268
- Oncology 430
Countries citing papers authored by Xiaoling Xu
This map shows the geographic impact of Xiaoling Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoling Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoling Xu more than expected).
Fields of papers citing papers by Xiaoling Xu
This network shows the impact of papers produced by Xiaoling Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoling Xu. The network helps show where Xiaoling Xu may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaoling Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 88 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Effective treatment of severe COVID-19 patients with tocilizumab Hit paper breakdown → | 2020 | 1879 |
| 2 | Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients Hit paper breakdown → | 2020 | 816 |
| 3 | Study of cardiovascular disease prediction model based on random forest in eastern China Hit paper breakdown → | 2020 | 242 |
| 4 | 2019 | 140 | |
| 5 | 2015 | 117 | |
| 6 | 2018 | 81 | |
| 7 | 2013 | 74 | |
| 8 | 2007 | 70 | |
| 9 | 2014 | 67 | |
| 10 | 2007 | 61 | |
| 11 | 2021 | 55 | |
| 12 | 2019 | 48 | |
| 13 | 2015 | 43 | |
| 14 | 2018 | 42 | |
| 15 | 2013 | 42 | |
| 16 | 2023 | 29 | |
| 17 | 2015 | 25 | |
| 18 | 2015 | 23 | |
| 19 | 2021 | 23 | |
| 20 | 2019 | 20 |
About Xiaoling Xu
Xiaoling Xu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Surgery and Epidemiology, having authored 88 papers that have together received 4.3k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (10 papers), Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Diagnosis and Treatment (6 papers), Cancer-related molecular mechanisms research (5 papers), Esophageal Cancer Research and Treatment (5 papers), COVID-19 Clinical Research Studies (4 papers) and Postharvest Quality and Shelf Life Management (4 papers). The work is most often cited by research in Infectious Diseases (2.0k citations), Neurology (1.1k citations), Obstetrics and Gynecology (136 citations), Cancer Research (268 citations) and Oncology (430 citations). Xiaoling Xu has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Haiming Wei, Xiaohu Zheng, Binqing Fu, Yonggang Zhou, Dongsheng Wang, Tiantian Li, Aijun Pan, Wei Sun, Yun Yang and Mingfeng Han. Their work appears in journals such as Frontiers in Oncology, OncoTargets and Therapy, Translational Lung Cancer Research, PLoS ONE and LWT.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.